Genetically proxied inhibition of L-2-hydroxyglutarate dehydrogenase reduces the risk of coronary artery disease: A Mendelian randomization study

Euijun Song, M.D.

Yonsei University College of Medicine, Seoul, Republic of Korea

Correspondence: drjunsong@gmail.com (Euijun Song, M.D.)

Conflict of interest: All authors have no financial conflicts of interest to declare.

Abstract

Backgrounds: L-2-hydroxyglutarate dehydrogenase (L2HGDH) deletion-induced L-2-hydroxyglutarate accumulation plays a cardioprotective role in hypoxic conditions. However, there has been no causal evidence in real-world clinical data. Here, we examine the causal effects of *L2HGDH* inhibition on coronary artery disease (CAD) and myocardial infarction (MI) using Mendelian randomization (MR) analysis.

Methods: We used nine *L2HGDH*-proxied genetic variants associated with blood 2-hydroxyglutarate levels as genetic instruments, and performed two-sample MR analysis using the CARDIoGRAMplusC4D meta-analysis datasets of CAD (60,801 CAD cases and 123,504 controls) and MI (34,541 MI cases and 261,984 controls).

Results: Genetically proxied inhibition of *L2HGDH* associated with 2-hydroxyglutarate levels potentially decreased the risk of CAD (odds ratio [OR] 0.486, 95% confidence interval [CI] 0.242–0.977, P=0.043) but was not associated with the risk of MI (OR 0.676, 95% CI 0.312–1.463, P=0.320). This potential causal association between *L2HGDH* inhibition and CAD was unlikely to be biased by horizontal pleiotropy.

Conclusions: The MR analysis suggests the potentially causal association between genetically proxied inhibition of *L2HGDH* and CAD. Our findings may have therapeutic implications for L2HGDH inhibitors in CAD, and further clinical studies are needed.

Keywords: L-2-hydroxyglutarate dehydrogenase; coronary artery disease; therapeutics; Mendelian randomization; metabolism

1. Introduction

L-2-hydroxyglutarate plays a pivotal role in cytoplasmic and mitochondrial energy metabolism to maintain redox regulation (1). Hypoxia increases cellular L-2-hydroxyglutarate, which is produced from α-ketoglutarate by malate dehydrogenase (1-3). L-2-hydroxyglutarate dehydrogenase (L2HGDH) is the only enzyme known to oxidize L-2-hydroxyglutarate back to α-ketoglutarate (2, 4). In experiments, *L2HGDH* ablation increases the accumulation of L-2-hydroxyglutarate in hypoxia (2, 5). L-2-hydroxyglutarate has been known to protect heart tissue from oxidative stress in response to hypoxia (5). Since coronary artery disease (CAD) leads to ischemic injury and ischemia-reperfusion injury, L-2-hydroxyglutarate may play a protective role in CAD and ischemic myocardial injury.

Metabolic remodeling plays a key role in the pathobiology of CAD and myocardial infarction (MI) (5-7). Recently, He and colleagues (5) discovered that genetic *L2HGDH* deletion-induced L-2-hydroxyglutarate accumulation shows cardioprotective effects under ischemic conditions in mice. They found that L-2-hydroxyglutarate accumulation shifts glucose metabolisms from glycolysis to the pentose phosphate pathway in response to low-flow ischemia or ischemia-reperfusion. This metabolic shift indicates that *L2HGDH* deletion-induced L-2-hydroxyglutarate accumulation could reduce ischemic myocardial damage by eliminating reactive oxygen species. The experiments suggest that *L2HGDH* is a potential therapeutic target for oxidative stress-related cardiovascular diseases, such as CAD and MI. However, there has been no prospective clinical trial yet.

One genetic epidemiological approach for testing the causal effects of drug targets on complex diseases is the Mendelian randomization (MR) method (8-12). MR methods can estimate the causal effects of putative risk factors based on germline genetic variation in the population, without conducting a randomized controlled trial. Using the MR framework, Ference and colleagues (8) successfully determined the causal associations of ATP citrate lyase (ACLY) and HMG-CoA reductase (HMGCR) inhibitions with the risk of cardiovascular disease. Similarly, MR approaches could identify potential causal effects of genetically proxied inhibition of cardiovascular drug targets on cancers, neuropsychiatric diseases, and cognitive function (9-12).

Here, we conduct a two-sample MR study to assess putative causal effects of genetically proxied inhibition of *L2HGDH* on CAD and MI (Figure 1). We construct genetic instruments for *L2HGDH* that are associated with blood 2-hydroxyglutarate levels. We then perform MR analysis to test whether this genetic instrument is causally associated with CAD and MI using large-scale genome-wide association study (GWAS) datasets.

2. Methods

2.1. Mendelian randomization study design

As illustrated in Figure 1, we designed a two-sample MR study to determine putative causal effects of genetically proxied inhibition of *L2HGDH* on CAD and MI. We first

81 construct the genetic instruments for *L2HGDH* to mimic pharmacological/genetic
82 perturbation of *L2HGDH* for increasing L-2-hydroxyglutarate levels. Due to the limited
83 availability of GWAS data for L-2-hydroxyglutarate levels, we constructed the genetic
84 instruments that are associated with 2-hydroxyglutarate level instead. We then
85 performed the Mendelian randomization analysis to determine potential causal
86 associations between the genetic instruments for *L2HGDH* and CAD using large-scale
87 GWAS summary statistics datasets.
88
89 **2.2. Genetic instruments for genetically proxied inhibition of *L2HGDH***
90 We obtained the GWAS summary statistics for human blood metabolome from Shin et
91 al (13). Shin et al. (13) analyzed >400 blood metabolites from the KORA and TwinsUK
92 European population datasets using the Metabolon platform. Since the Metabolon
93 platform could not distinguish L-2-hydroxyglutarate from D-2-hydroxyglutarate, we
94 alternatively used the GWAS data for 2-hydroxyglutarate levels to construct the genetic
95 instruments for *L2HGDH*.
96
97 L2HGDH is the only enzyme known to catabolize L-2-hydroxyglutarate in human cells,
98 and L2HGDH inhibition increases L-2-hydroxyglutarate levels in experiments (1, 2). We
99 constructed the genetic instruments for *L2HGDH* by recruiting genetic variants within ±
100 500 kb from the *L2HGDH* gene that are associated with blood 2-hydroxyglutarate level
101 ($P<0.05$) and that are also in low linkage disequilibrium ($r^2<0.3$, with the default
102 clumping window setting of TwoSampleMR) (8). These weak P-value and r^2 thresholds
103 were suggested previously by Ference and colleagues (8). The SNPs and *L2HGDH*

gene were analyzed based on the GRCh37 (hg19) human genome reference (Figure S1). The characteristics of genetic variants proxied to *L2HGDH* are shown in Table S1.

2.3. Data sources for CAD and MI

The GWAS summary statistics for CAD was obtained from the CARDIoGRAMplusC4D (Coronary Artery DIsease Genome-wide Replication and Meta-analysis plus Coronary Artery Disease) 1000 Genomes-based GWAS meta-analysis study (http://www.cardiogramplusc4d.org) (14). The CARDIoGRAMplusC4D GWAS meta-analysis dataset included genetic associations from 60,801 CAD cases and 123,504 controls mostly of European ancestry. The case status was defined by diagnosis of CAD, including MI, acute coronary syndrome, chronic stable angina, and coronary stenosis >50% (14). In addition, the MI GWAS summary statistics was obtained from the same CARDIoGRAMplusC4D meta-analysis study (34,541 MI cases and 261,984 controls). All the MI cases are a subpopulation of the CAD cases (14).

2.4. Mendelian randomization and statistical analysis

For MR analysis, the instrument strength was measured using the Cragg–Donald F-statistic (15) as $F = \left(\frac{n-k-1}{k}\right) \cdot \left(\frac{R^2}{1-R^2}\right)$, where n is the sample size, k is the number of the genetic variants, and R^2 is the proportion of variance explained by the genetic variants. The F-statistic less than 10 indicates weak instruments. We used the inverse-variance weighted (IVW), weighted median, maximum likelihood, MR-PRESSO (16), and Radial-MR (17) methods to evaluate the putative causal effects of genetically proxied inhibition of *L2HGDH* on CAD and MI. The heterogeneity between SNPs was evaluated by

127 Cochran's Q test (18). We also performed the MR Steiger directionality test to
128 determine the directionality of causality (19). To assess potential directional and
129 horizontal pleiotropy, we used the MR-Egger intercept test and MR-PRESSO methods.
130 The leave-one-out sensitivity analysis and Radial-MR were used to detect potential
131 outlying genetic variants. P<0.05 was considered statistically significant. All MR
132 analyses were performed in R (version 4.1.2, https://www.r-project.org/) with the
133 packages TwoSampleMR, MRPRESSO, and RadialMR.
134
135

136 ## 3. Results

137 ### 3.1. Genetic instruments for *L2HGDH*

138 We first constructed the genetic instruments proxied to *L2HGDH* that are associated
139 with blood 2-hydroxyglutarate levels (P<0.05) and that are also in low linkage
140 disequilibrium (r^2<0.3; Table S1). Since there was no genome-wide significant variant
141 associated with 2-hydroxyglutarate levels near the *L2HGDH* gene (Table S2), we
142 adopted a loose significance threshold of 0.05 to construct instruments for genetically
143 proxied inhibition of *L2HGDH* (8). These genetic instruments mimic genetic or
144 pharmacological inhibition of *L2HGDH* for increasing blood 2-hydroxyglutarate levels
145 (Figure 1). The genetic instruments have the F-statistic of >10, indicating that there
146 might be a slight weak instrument bias in our MR analysis. All the nine SNPs are also
147 included in the outcome (i.e., CAD or MI) datasets.
148

149 ### 3.2. Association of genetically proxied inhibition of *L2HGDH* with CAD and MI

150 We performed a two-sample MR analysis using the CARDIoGRAMplusC4D GWAS
151 meta-analysis dataset of CAD (60,801 CAD cases and 123,504 controls). As highlighted
152 in Table 1, the inverse-variance weighted (IVW) method showed that genetically proxied
153 inhibition of *L2HGDH* associated with 2-hydroxyglutarate levels potentially decreased
154 the risk of CAD (OR 0.486, 95% CI 0.242–0.977, P=0.043). There was no evidence of
155 heterogeneity (Cochran's Q-statistic=5.757, P=0.674). The radial IVW, weighted
156 median, and maximum likelihood methods also showed directionally similar estimates
157 (Table 1). The MR Steiger directionality test further confirmed the direction of the
158 causality (P<0.001).
159
160 To assess potential directional horizontal pleiotropy, we used the MR-Egger and MR-
161 PRESSO methods. The MR-Egger intercept test determined that 9 genetic variants for
162 *L2HGDH* showed no evidence for significant pleiotropy (intercept=-0.014, P=0.396).
163 The MR-PRESSO global test also confirmed no significant horizontal pleiotropy with no
164 outlying genetic variants (P=0.715). In addition, the leave-one-out sensitivity analysis
165 showed that removing individual genetic variants did not substantially change the
166 estimated causal effect of genetically proxied inhibition of *L2HGDH* (Table S3). The
167 radial IVW method further confirmed no evidence of outlying genetic variants (Figure
168 S2). Taken together, the sensitivity analyses provide no significant evidence for
169 pleiotropic effects, which could bias the MR analyses.
170
171 As a subpopulation of the CAD cases, we also examined the putative causal
172 association between *L2HGDH* inhibition and MI using the CARDIoGRAMplusC4D meta-

173 analysis dataset of MI (34,541 MI cases and 261,984 controls). Using IVW, we found
174 that genetically proxied inhibition of *L2HGDH* was not significantly associated with the
175 risk of MI (OR 0.676, 95% CI 0.312–1.463, P=0.320). The MR-Egger intercept and MR-
176 PRESSO global tests indicated no significant pleiotropy (Table 1), and the radial plot
177 indicated no evidence of outlying variants (Figure S2).
178
179

180 4. Discussion

181 To our knowledge, this is the first MR study to demonstrate the potential causal
182 association between genetically proxied inhibition of *L2HGDH* and CAD. Using large-
183 scale MR analyses, we revealed that genetically proxied inhibition of *L2HGDH* was
184 significantly associated with the decreased risk of CAD. The multiple MR sensitivity
185 analyses confirmed that this potential causal association was unlikely to be biased by
186 horizontal pleiotropy. Our findings suggests that genetic/pharmacological targeting of
187 *L2HGDH* may decrease the risk of CAD by increasing blood 2-hydroxyglutarate levels.
188
189 In the previous experimental study, *L2HGDH* deletion-induced L-2-hydroxyglutarate
190 accumulation protects the heart from redox stress, which plays a key role in myocardial
191 ischemic injury (5). However, there has been no clinical trial to validate this potential
192 cardioprotective effect of *L2HGDH* inhibition. Using large-scale MR, we revealed that
193 genetically proxied inhibition of *L2HGDH* could potentially decrease the risk of CAD but
194 was not significantly associated with MI *per se* (Table 1). In our MR study, the CAD
195 cases include MI, acute coronary syndrome, coronary atherosclerosis, and chronic

196 ischemic heart diseases. Therefore, our findings suggest that *L2HGDH* inhibition may
197 play a cardioprotective role in not only being limited to myocardial ischemic damage, but
198 also in the primary prevention of CAD. The mechanisms underlying the potential
199 preventive effects of *L2HGDH* inhibition on CAD should be further investigated.
200
201 Due to the limited availability of GWAS data on blood metabolome, we constructed
202 genetic instruments based on blood 2-hydroxyglutarate levels, including its two
203 enantiomers L-2-hydroxyglutarate and D-2-hydroxyglutarate. D-2-hydroxyglutarate has
204 been known to be an oncometabolite in certain types of rare cancers (20, 21). To
205 minimize the effects of D-2-hydroxyglutarate in our MR analysis, we constructed the
206 genetic instruments only proxied to the *L2HGDH* gene. In experiments, L-2-
207 hydroxyglutarate is the majority of 2-hydroxyglutarate, and *L2HGDH* but not D2HGDH
208 knockdown increases the concentration of 2-hydroxyglutarate (1, 2). Additionally,
209 L2HGDH is the only reported enzyme that metabolizes L-2-hydroxyglutarate. Therefore,
210 our approach would mainly reflect *L2HGDH* inhibition-related L-2-hydroxyglutarate
211 levels; however, large-scale GWAS data of blood L-2-hydroxyglutarate levels is
212 essential to obtain more robust and accurate MR results. Since L-2-hydroxyglutarate is
213 also a putative oncometabolite in renal cell carcinoma (22, 23), further
214 epidemiological/clinical studies are warranted to determine the potential side effects of
215 *L2HGDH* inhibition.
216
217 A potential limitation of this study is that we adopted a loose P-value threshold of 0.05 to
218 build the genetic instruments (8). When we used the genome-wide significance

threshold, there was no genetic variant associated with blood 2-hydroxyglutarate levels, near the *L2HGDH* gene (Table S2). Since L2HGDH is the only enzyme known to metabolize L-2-hydroxyglutarate, we only considered *L2HGDH*-proxied variants to reflect the physiological effects of *L2HGDH* inhibition on L-2-hydroxyglutarate levels (1, 2). In addition, we did not perform any replication analysis in non-European populations, though the CARDIoGRAMplusC4D is the largest consortium study of CAD. In our MR analysis, the weighted median methods did not show significant results; however, those methods are statistically less powerful than IVW (24). Large-scale multi-ancestry GWAS datasets for L-2-hydroxyglutarate are essential to construct more robust genetic instruments. Protein-protein interaction network analysis would be helpful to determine the functional relationship between L2HGDH and the CAD disease module and to identify potential drug targets (25, 26).

Authorship contribution

Euijun Song designed, performed, analyzed data, and wrote the manuscript.

Acknowledgements

This research received no external funding. This study only used publicly available GWAS summary statistics datasets. The author thanks Drs. Joseph Loscalzo and Feixiong Cheng for insightful discussions and comments.

241 ## References

242 1. Oldham WM, Clish CB, Yang Y, Loscalzo J. Hypoxia-Mediated Increases in L-2-
243 hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell
244 Metab. 2015;22(2):291-303.
245 2. Intlekofer AM, Dematteo RG, Venneti S, Finley LW, Lu C, Judkins AR, et al.
246 Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metab.
247 2015;22(2):304-11.
248 3. Chakraborty AA, Laukka T, Myllykoski M, Ringel AE, Booker MA, Tolstorukov
249 MY, et al. Histone demethylase KDM6A directly senses oxygen to control
250 chromatin and cell fate. Science. 2019;363(6432):1217-22.
251 4. Rzem R, Veiga-da-Cunha M, Noel G, Goffette S, Nassogne MC, Tabarki B, et al.
252 A gene encoding a putative FAD-dependent L-2-hydroxyglutarate
253 dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc Natl Acad Sci U
254 S A. 2004;101(48):16849-54.
255 5. He H, Mulhern RM, Oldham WM, Xiao W, Lin YD, Liao R, et al. L-2-
256 Hydroxyglutarate Protects Against Cardiac Injury via Metabolic Remodeling. Circ
257 Res. 2022;131(7):562-79.
258 6. Xiao W, Oldham WM, Priolo C, Pandey AK, Loscalzo J. Immunometabolic
259 Endothelial Phenotypes: Integrating Inflammation and Glucose Metabolism. Circ
260 Res. 2021;129(1):9-29.
261 7. Lee LY, Oldham WM, He H, Wang R, Mulhern R, Handy DE, et al. Interferon-
262 gamma Impairs Human Coronary Artery Endothelial Glucose Metabolism by
263 Tryptophan Catabolism and Activates Fatty Acid Oxidation. Circulation.
264 2021;144(20):1612-28.
265 8. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al.
266 Mendelian Randomization Study of ACLY and Cardiovascular Disease. N Engl J
267 Med. 2019;380(11):1033-42.
268 9. Yarmolinsky J, Diez-Obrero V, Richardson TG, Pigeyre M, Sjaarda J, Pare G, et
269 al. Genetically proxied therapeutic inhibition of antihypertensive drug targets and
270 risk of common cancers: A mendelian randomization analysis. PLoS Med.
271 2022;19(2):e1003897.

272 10. Sun L, Ding H, Jia Y, Shi M, Guo D, Yang P, et al. Associations of genetically
273 proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast
274 cancer and prostate cancer. Breast Cancer Res. 2022;24(1):12.
275 11. Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW**.** Mendelian
276 Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and
277 Cognitive Function. J Am Coll Cardiol. 2022;80(7):653-62.
278 12. Bell AS, Rosoff DB, Mavromatis LA, Jung J, Wagner J, Lohoff FW**.** Comparing
279 the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders,
280 Cognition, and Dementia Between Men and Women: A Drug-Target Mendelian
281 Randomization Study. J Am Heart Assoc. 2022;0(0):e026122.
282 13. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, et al. An
283 atlas of genetic influences on human blood metabolites. Nat Genet.
284 2014;46(6):543-50.
285 14. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A
286 comprehensive 1,000 Genomes-based genome-wide association meta-analysis
287 of coronary artery disease. Nat Genet. 2015;47(10):1121-30.
288 15. Burgess S, Thompson SG, Collaboration CCG**.** Avoiding bias from weak
289 instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755-
290 64.
291 16. Verbanck M, Chen CY, Neale B, Do R**.** Detection of widespread horizontal
292 pleiotropy in causal relationships inferred from Mendelian randomization between
293 complex traits and diseases. Nat Genet. 2018;50(5):693-8.
294 17. Bowden J, Spiller W, Del Greco MF, Sheehan N, Thompson J, Minelli C, et al.
295 Improving the visualization, interpretation and analysis of two-sample summary
296 data Mendelian randomization via the Radial plot and Radial regression. Int J
297 Epidemiol. 2018;47(4):1264-78.
298 18. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG**.** Sensitivity Analyses
299 for Robust Causal Inference from Mendelian Randomization Analyses with
300 Multiple Genetic Variants. Epidemiology. 2017;28(1):30-42.

301 19. Hemani G, Tilling K, Davey Smith G**.** Orienting the causal relationship between
302 imprecisely measured traits using GWAS summary data. PLoS Genet.
303 2017;13(11):e1007081.
304 20. Rakheja D, Medeiros LJ, Bevan S, Chen W**.** The emerging role of d-2-
305 hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous
306 system neoplasms. Front Oncol. 2013;3:169.
307 21. Jezek P**.** 2-Hydroxyglutarate in Cancer Cells. Antioxid Redox Signal.
308 2020;33(13):903-26.
309 22. Shelar S, Shim EH, Brinkley GJ, Kundu A, Carobbio F, Poston T, et al.
310 Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential
311 Therapeutic Target in Renal Cancer. Clin Cancer Res. 2018;24(24):6433-46.
312 23. Shim EH, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, et al. L-2-
313 Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal
314 cancer. Cancer Discov. 2014;4(11):1290-8.
315 24. Bowden J**.** Misconceptions on the use of MR-Egger regression and the
316 evaluation of the InSIDE assumption. Int J Epidemiol. 2017;46(6):2097-9.
317 25. Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabasi AL, et al.
318 Network-based approach to prediction and population-based validation of in silico
319 drug repurposing. Nat Commun. 2018;9(1):2691.
320 26. Lee LY, Pandey AK, Maron BA, Loscalzo J**.** Network medicine in Cardiovascular
321 Research. Cardiovasc Res. 2021;117(10):2186-202.
322



Figure 1. Overall analysis scheme. (A) Function of L-2-hydroxyglutarate dehydrogenase (L2HGDH) in energy metabolisms. Inhibition of L2HGDH increases blood L-2-hydroxyglutarate levels. (B) We constructed genetic instruments proxied to the *L2HGDH* gene that are associated with blood 2-hydroxyglutarate levels. We then performed two-sample Mendelian randomization analysis to assess the causal effects of genetically proxied inhibition of *L2HGDH* on coronary artery disease and myocardial infarction.

332 **Table 1.** Mendelian randomization (MR) analyses for causal associations of genetically proxied inhibition of *L2HGDH* with

333 coronary artery disease and myocardial infarction.

	Coronary artery disease (60,801 cases, 123,504 controls)			**Myocardial infarction** (34,541 cases, 261,984 controls)		
	OR (95% CI)	**P-value**	**SNPs**	**OR (95% CI)**	**P-value**	**SNPs**
IVW	0.486 (0.242–0.977)	0.043	9	0.676 (0.312–1.463)	0.320	9
IVW (Radial)	0.487 (0.269–0.880)	0.017	9	0.676 (0.361–1.268)	0.222	9
Weighted median	0.762 (0.300–1.937)	0.568	9	0.888 (0.325–2.428)	0.817	9
Maximum likelihood	0.457 (0.216–0.967)	0.041	9	0.655 (0.291–1.476)	0.308	9
MR-Egger intercept*	-0.014 (0.016)	0.396	9	-0.004 (0.017)	0.836	9
MR-PRESSO global[#]	-	0.715	9	-	0.752	9
MR Steiger directionality	-	<0.001	9	-	<0.001	9

334 SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted method.

335 *Intercept values are presented with SE.

336 [#]No outlying genetic variants were detected.

337

338 **Supplementary materials**

339



340

341 **Figure S1.** Genomic positions of nine genetic instruments for genetically proxied

342 inhibition of *L2HGDH*. The genomic positions were visualized using the NCBI Graphical

343 Sequence Viewer (GRCh37, accessed on Oct 29, 2022).

344



Figure S2. Radial inverse-variance weighted (IVW) Mendelian randomization plots for coronary artery disease (A) and myocardial infarction (B). Black dots indicate valid genetic variants. The estimated effect sizes are presented. There is no outlier variant in the present radial plots.

351 **Table S1.** Nine *L2HGDH*-proxied (± 500 kb) genetic variants that are associated with

352 blood 2-hydroxyglutarate levels ($P<0.05$, $r^2<0.3$).

SNP	Position (GRCh37)	Effect/other allele	EAF	β (SE)*	P-value
rs11628742	chr14:50515075	C/T	0.438	-0.0112 (0.0043)	9.02×10^{-3}
rs11625406	chr14:50516192	A/C	0.619	0.0070 (0.0033)	3.56×10^{-2}
rs8017367	chr14:50675487	T/C	0.261	-0.0121 (0.0034)	4.00×10^{-4}
rs12894758	chr14:50760030	T/C	0.291	0.0135 (0.0034)	6.80×10^{-5}
rs9323183	chr14:50796881	C/G	0.054	-0.0150 (0.0071)	3.37×10^{-2}
rs11570815	chr14:50825258	T/A	0.662	0.0094 (0.0033)	4.88×10^{-3}
rs17791680	chr14:50965445	A/G	0.372	-0.0081 (0.0034)	1.64×10^{-2}
rs2144975	chr14:50969448	C/T	0.955	0.0170 (0.0075)	2.44×10^{-2}
rs2012893	chr14:51073443	G/A	0.088	-0.0145 (0.0060)	1.53×10^{-2}

353 SNP, single nucleotide polymorphism; EAF, effective allele frequency.

354 *Log(odds ratio) per 1-SD increase in blood 2-hydroxyglutarate levels.

355

356 **Table S2.** Genetic variants associated with blood 2-hydroxyglutarate levels ($P<1x10^{-5}$,

357 $r^2<0.3$).

SNP	Position (GRCh37)	Effect/other allele	EAF	β (SE)*	P-value
rs10196007	chr2:145329033	C/T	0.184	0.0320 (0.0065)	$7.63x10^{-7}$
rs1568101	chr3:148590090	T/C	0.912	-0.0255 (0.0057)	$8.62x10^{-6}$
rs7725624	chr5:63010725	A/C	0.087	-0.0440 (0.0094)	$3.02x10^{-6}$
rs7702827	chr5:158879869	G/C	0.700	0.0152 (0.0034)	$6.29x10^{-6}$
rs933341	chr7:83743619	G/A	0.760	-0.0166 (0.0035)	$1.56x10^{-6}$
rs8176023	chr7:142642596	G/A	0.072	0.0411 (0.0087)	$2.46x10^{-6}$
rs890519	chr8:18905049	A/C	0.416	0.0147 (0.0033)	$9.06x10^{-6}$
rs10966201	chr9:24079188	C/T	0.345	-0.0151 (0.0034)	$7.11x10^{-6}$
rs11793331	chr9:133298199	T/C	0.024	0.0619 (0.0136)	$5.09x10^{-6}$
rs6484669	chr11:11120287	C/T	0.259	0.0196 (0.0044)	$7.75x10^{-6}$
rs9544785	chr13:78971070	A/C	0.361	-0.0150 (0.0033)	$6.63x10^{-6}$
rs16977497	chr17:71021645	A/G	0.045	0.0538 (0.0122)	$9.91x10^{-6}$
rs6064820	chr20:58206004	T/C	0.723	0.0155 (0.0034)	$4.01x10^{-6}$

358 SNP, single nucleotide polymorphism; EAF, effective allele frequency.

359 *Log(odds ratio) per 1-SD increase in blood 2-hydroxyglutarate levels.

360

361 **Table S3.** Leave-one-out sensitivity analyses for the causal associations of genetically
362 proxied *L2HGDH* inhibition with coronary artery disease and myocardial infarction using
363 the inverse-variance weighted method.

	Coronary artery disease		**Myocardial infarction**	
Removed SNP	**OR (95% CI)**	**P-value**	**OR (95% CI)**	**P-value**
rs2144975	0.576 (0.277–1.194)	0.138	0.826 (0.369–1.847)	0.641
rs11570815	0.545 (0.259–1.150)	0.111	0.770 (0.337–1.758)	0.535
rs11625406	0.535 (0.260–1.103)	0.090	0.715 (0.321–1.590)	0.410
rs17791680	0.499 (0.240–1.036)	0.062	0.668 (0.297–1.499)	0.328
rs9323183	0.461 (0.225–0.945)	0.035	0.644 (0.291–1.425)	0.278
rs2012893	0.457 (0.222–0.941)	0.034	0.657 (0.296–1.461)	0.304
rs8017367	0.455 (0.212–0.979)	0.044	0.553 (0.237–1.289)	0.170
rs11628742	0.445 (0.209–0.947)	0.036	0.625 (0.271–1.442)	0.270
rs12894758	0.411 (0.188–0.899)	0.026	0.648 (0.272–1.542)	0.326
None (original)	0.486 (0.242–0.977)	0.043	0.676 (0.312–1.463)	0.320

364 SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

365